Larimar Therapeutics, Inc. (LRMR) Financial Analysis & Valuation | Quarter Chart
Larimar Therapeutics, Inc. (LRMR)
LRMRPrice: $4.55
Fair Value: 🔒
🔒score
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxi... more
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments... more
Description
Shares
| Market Cap | $389.81M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Carole S. Ben-Maimon |
| IPO Date | 2014-06-19 | CAGR | — |
| Employees | 65 | Website | www.larimartx.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
LRMR chart loading...
Fundamentals
Technicals
| Enterprise Value | $243.20M | P/E Ratio | -1.59 |
| Forward P/E | -2.66 | PEG Ratio | — |
| P/S Ratio | — | P/B Ratio | 4.97 |
| P/CF Ratio | -3.43 | P/FCF Ratio | -3.44 |
| EPS | $-1.96 | EPS Growth 1Y | 70% |
| EPS Growth 3Y | 31.55% | EPS Growth 5Y | -36.13% |
| Revenue Growth 1Y | — | Gross Margin | — |
| Operating Margin | — | Profit Margin | — |
| ROE | -1.38% | ROA | -1.14% |
| ROCE | -2.13% | Current Ratio | 2.19 |
| Quick Ratio | 2.19 | Cash Ratio | 1.32 |
| Debt/Equity | 0.05 | Interest Coverage | — |
| Altman Z Score | -4 | Piotroski Score | 1 |